blood cancers

How Gamida Cell’s FDA Approval Could Reduce Racial Disparities in Stem Cell Transplants
How Gamida Cell’s FDA Approval Could Reduce Racial Disparities in Stem Cell Transplants
MedCity News
Gamida Cell
FDA
Omisirge
cell therapy
blood cancers
Flag link:
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
Fierce Pharma
BeiGene
AbbVie
JNJ
Imbruvica
blood cancers
Brukinsa
Flag link:
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers
Businesswire
Gamida Cell
solid tumors
blood cancers
omidubicel
Flag link:
FDA's oncology adcomm to review PI3K inhibitors in blood cancers in April
FDA's oncology adcomm to review PI3K inhibitors in blood cancers in April
Endpoints
FDA
regulatory
blood cancers
PI3k inhibitor
Flag link:
ASH: Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma
ASH: Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma
Endpoints
ASH2021
Roche
antibody-drug conjugate
Polivy
Genentech
blood cancers
Flag link:
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
Flag link:
FDA approves PharmaEssentia interferon drug for a rare type of blood cancer
FDA approves PharmaEssentia interferon drug for a rare type of blood cancer
MedCity News
PharmaEssentia
FDA
interferon
blood cancers
polycythemia vera
ropeginterferon alfa
Flag link:
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Fierce Biotech
Novartis
Xencor
bispecifics
blood cancers
Flag link:
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
Fierce Biotech
JNJ
Xencor
biobucks
Roche
Regeneron
bispecific antibodies
blood cancers
plamotamab
Flag link:
Imago BioSciences raises $80M to advance blood cancer therapy
Imago BioSciences raises $80M to advance blood cancer therapy
Fierce Biotech
blood cancers
Imago BioSciences
Flag link:
ExCellThera launches trial of drug to expand umbilical cord blood for stem-cell transplants in cancer
ExCellThera launches trial of drug to expand umbilical cord blood for stem-cell transplants in cancer
Fierce Biotech
ExCellThera
umbilical cord blood
cord blood
stem cells
blood cancers
Flag link:
This Could Be a Big Year for Incyte
This Could Be a Big Year for Incyte
Motley Fool
Incyte
Jakafi
blood cancers
Flag link:
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
Fierce Biotech
Argenx
Cilag
Janssen
cusatuzumab
ASH2018
blood cancers
Flag link:
Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals
Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals
Fierce Biotech
Amgen
MD Anderson Cancer Center
drug development
blood cancers
Small-Cell Lung Cancer
Flag link:
AbbVie Expects Imbruvica Revenues to Reach $5 Billion in 2020
AbbVie Expects Imbruvica Revenues to Reach $5 Billion in 2020
Yahoo/Market Realist
AbbVie
Imbruvica
blood cancers
Flag link:
Epizyme parts ways with its CEO ahead of big Phase II cancer bet
Epizyme parts ways with its CEO ahead of big Phase II cancer bet
Fierce Biotech
Epizyme
Robert Gould
blood cancers
Flag link: